Last fall, three UCSF professors who are long-time associates of the Diabetes Center both received one of the nation's highest honors in the fields of medicine and health. On Oct. 18, 2004, Fred Cohen, MD, DPhil, Professor of Cellular and Molecular Pharmacology and Arthur Weiss, MD, PhD, Professor of Medicine and Chief of the Division of Rheumatology were elected to the Institute of Medicine (IOM) of the National Academies.
The body's rejection of transplanted organs and tissues is an unfortunate risk of transplant surgery. Historically, rejection rates in a simultaneous pancreas-kidney (SPK) transplant have been as high as 80% and, in 2001, averaged nearly 20% . What's more, steroid-based immunosuppressive drugs that have been traditionally used to combat rejection are associated with several serious side-effects, including increased risks of osteoporosis and bone and joint problems.
A new tool that gives researchers the ability to block disease-causing genes is the next wave in biotechnology. If successful, “RNA interference” (known as RNAi) could provide new cures for everything from cancer to HIV to diabetes. Dr. Michael McManus, a world leader in RNAi, recently moved his MIT laboratory to the Diabetes Center at UCSF to focus his groundbreaking research on the problem of diabetes.
Information on clinical trials conducted by Diabetes Center at UCSF researchers is now available online through the Diabetes Center website. Users can access an up-to-date list of UCSF clinical trials in type 1 and type 2 diabetes that are seeking to enroll patients, with information on each trial as well as study contacts to find out more about eligibility and enrollment.
Modern successful human organ transplantation has only been around since the 1960s. However, in the relatively short time since then, the number of diseases in which transplantation is a viable and recommended treatment has grown at an impressive rate. So too has grown the need for organ transplants in patients with type 1 diabetes.
On Election Day, California voters approved Proposition 71, the California Stem Cell Research and Cures Initiative, by a margin of 59% to 41%. In passing Prop 71, voters agreed to fund stem cell research at California hospitals, medical schools and universities to help develop potentially lifesaving therapies and cures for diseases that affect the lives of over 128 million Americans.
The Diabetes Center's second annual Pediatric Diabetes Symposium and Kids Kamp, held this year on Saturday, October 9 was a rousing success. Nearly 200 parents and children attended the symposium to learn the latest in diabetes research and clinical care from respected UCSF-affiliated researchers and clinicians, while the little ones enjoyed the Novo Nordisk-sponsored "Kids Kamp."
A brain protein already known to play a central role in the "feast or fast" signaling that controls the urge to eat has now been found to influence appetite in a second way. The discovery identifies a potential new target for drugs against obesity.
Even though Jason DeVoss, PhD has been working in Dr. Mark Anderson's lab for less than a year, he is already making his mark by creating a promising, new ophthalmology model that may make it easier to study diabetic complications in the eye.
As a young research investigator and clinician, Mark Anderson, MD, PhD, has wasted no time in making his mark in diabetes. First, he attracts worldwide attention by uncovering an important protein that helps immune cells learn how to recognize and avoid attacking the body's own tissue.
The Juvenile Diabetes Research Foundation (JDRF) will award its highest honor for basic diabetes research to Jeffrey Bluestone, PhD, an internationally recognized leader in autoimmunity research and the director of the Diabetes Center at UCSF. Bluestone will receive the Gerold & Kayla Grodsky Basic Science Award at a JDRF event May 21 in Manhattan.